Page 1

Corporate News ● M1 Kliniken AG publishes figures for the 1st quarter of 2021 : successful start to 2021 with significant increase in revenues and earnings in both business segments Group turnover rises to almost EUR 81 million ( EUR 23 million in Q1-2020 ) Group EBITDA amounts to EUR 4.0 million ( previous year : EUR 1.4 million ) ; EBIT amounts to EUR 2.6 million ( previous year : EUR 0.5 million ) ● mi Kliniker Kliniken AG Beauty : After restrained treatment figures at the beginning of the quarter , significant increase compared to the previous year at the end of the quarter • Trade : Continuation of operational optimisations - sales / result still without effects of COVID antigen rapid tests Berlin , 1.06.2021 - M1 Kliniken AG ( ISIN : DE000A0STSQ8 ) announces figures for the first quarter of 2021. According to these figures , the consolidated group revenue of the M1 Group in the first quarter of the financial year 2021 rose by approx . 250 % year - on - year to just under EUR 81 million ( previous year : EUR 23 million ) . Of this , HAEMATO AG ( without M1 Aesthetics ) , which was not yet consolidated in the same period of the previous year , accounted for sales of a good EUR 59 million . In the beauty segment , the start into the new year was very restrained due to Corona , with treatment figures that were significantly below the previous year ( -20 % ) . Towards the end of the quarter , this picture turned around , so that M1 was able to reach and further increase its historical peak daily sales several times in a row . In Q1-2021 as a whole , just over 81 thousand treatments were performed compared to 73 thousand treatments in the same quarter last year . Turnover in the Beauty segment rose to EUR 13 million after EUR 11.5 million in the previous year . The development in the international locations was particularly pleasing , with treatment numbers increasing from just under 4 thousand ( Q1-2020 ) to over 7 thousand ( Q1-2021 ) . Since 12 April 2021 , the two locations in the UK have also been reopened , which achieved very pleasing occupancy rates right from the start . In the trading segment , the ongoing operational optimisation of the business activities of HAEMATO AG is particularly noteworthy , which was able to report a further increase in turnover in the past quarter compared to the previous year . HAEMATO AG was able to significantly improve its profitability . These figures do not yet include the effects of the antigen rapid test approved by the Federal Institute for Drugs and Medical Devices ( BfArM ) on 23 March 2021 in accordance with Section 11 ( 1 ) of the German Medical Devices Act ( MPG ) , the sales of which will significantly positively strengthen the sales and earnings of HAEMATO AG from April . Contact : M1 Kliniken AG Grünauer Straße 5 : D 12557 Berlin : EBITDA of M1 Kliniken AG in Q1-2021 totalled EUR 4.0 million ( previous year : EUR 1.4 million ) , EBIT amounted to EUR 2.6 million ( previous year : EUR 0.5 million ) . The previous year was marked by the first foothills of the Corona pandemic with the closure of all sites from 23 March 2020. In addition , development and start - up losses of the international sites still burdened the earnings +49 ( 0 ) 30 34 74 74 - 410 +49 ( 0 ) 30 34 74 74 - 417 M : ir@m1-kliniken.de W : www.m1-kliniken.de